- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01071460
Evaluation of Efficacy and Safety of the FlexStent Self-Expanding Stent System
The FlexStent-Registry, Evaluation of Efficacy and Safety of the FlexStent Femoropopliteal Self-Expanding Stent System
Purpose of this registry is to determine the efficacy and safety of the self-expanding, extra flexible FlexStent in patient with superficial femor/popliteal artery disease.
The stent has been developed to cope with the extreme requirements of the femoral artery/knee artery and is approved for usage at humans (EC-certified). It is designed to treat narrows of the femoral- and knee artery.
100 patients at 5 German hospital shall be enrolled. After stent implantation follow-up visits at 6 and 12 month take place.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Peripheral arterial disease (PAD) represents a major challenge to physicians in treating the Superficial Femoral (SFA) and Popliteal arteries. These arteries represent a harsh environment for any endovascular device. This disease is characterized by long occlusions with relatively low flow and with the vessels exposed to enormous mechanical stress. During flexing of the knee, the SFA/Popliteal arteries can bend, rotate, elongate and compress dramatically. An ideal stent designed for use in the SFA/Popliteal arteries would offer great ranges of movement while adequately supporting the arteries.
The FlexStent® stent provides a great range of motions for a highly flexible femoral artery while adequately supporting the vessel. The intended use for the FlexStent® stent is for the treatment of symptomatic femoropopliteal disease, primarily for atherosclerotic de novo native superficial femoral artery lesions.
The intent of this clinical registry is to demonstrate the efficacy and safety of the FlexStent® stent in patients with superficial femoral/ popliteal artery disease.
Hypothesis: the FlexStent® will be safe and efficacious in treating SFA/popliteal artery diseases.
Primary object: evaluation of efficacy of the FlexStent® measured by the in-stent restenosis using DUS following treatment, 6 and 12 MFU visits.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bad Krozingen, Germany, 79189
- Herz-Zentrum Bad Krozingen Abteilung Angiologie
-
Berlin, Germany, 13347
- Jüdisches Krankenhaus Berlin, Gefäßzentrum
-
Leipzig, Germany, 04289
- Park-Krankenhaus Leipzig
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects, male or female, must be between the ages of 35 to 85 years inclusive at the time of consent. A female of childbearing potential may be enrolled, provided she has a negative pregnancy test at Screening.
- Subjects must give written informed consent prior to participation in the study and must understand the purpose of this study and be willing to adhere to the study procedures described in this protocol.
- Rutherford Classification Category 2-4
- Single de novo lesion in the superficial femoro/popliteal artery
Disease segment length ≤150mm
->70% diameter stenosis and occlusion
- Patent ipsilateral iliac artery
- Patent ipsilateral popliteal artery and at least 1 patent tibial artery in continuity to ankle
- Target reference vessel diameter 3.5-7.5 mm
Exclusion Criteria:
- Target lesion previously treated with a stent or surgery.
- Rutherford Classification Category 0,1,5 or 6.
- Inability to tolerate antithrombotic or antiplatelet therapies.
- Pregnancy.
- Other comorbidity risks which in the opinion of the investigator limit longevity or likelihood of complying with protocol follow up.
- Serum creatinine > 2.5 mg/dL.
- Myocardial infarction or stroke within 90 days of enrollment.
- Hypercoagulable state.
- Uncontrollable hypertension.
- Patients currently enrolled in any other clinical trial(s).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: SFA Stenting
|
Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
in-stent binary restenosis using DUS
Time Frame: after treatment, at 6 and 12 MFU
|
after treatment, at 6 and 12 MFU
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
technical success, defined as the ability to implant the stent with a residual angiographic stenosis no greater than 30%
Time Frame: at 6 and 12 MFU
|
at 6 and 12 MFU
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dierk Scheinert, Professor, Park-Krankenhaus Leipzig
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Prov 01-2009
- 147-2009-06072009 (Other Identifier: Ethic Committee at the University of Leipzig, Germany)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Efficacy of the Study Device
-
Fundació Institut de Recerca de l'Hospital de la...CompletedTo Determine the Efficacy of Two Liquid Oxygen DeviceSpain
-
Lee's Pharmaceutical LimitedFidia Farmaceutici s.p.a.CompletedThe Primary Objective of This Study Was to Assess the Efficacy and Safety of Hyaluronic Acid Vaginal Gel in Treating Vaginal Dryness
-
St. Vincent's Medical CenterUnknownThis Study Has Been Designed to Compile Information on the Efficacy of the Partial Breast Intracavitary Brachytherapy in the Post Market Setting.United States
-
Optina Diagnostics Inc.Sunnybrook Health Sciences CentreWithdrawn
-
University of California, San DiegoCompletedMedical Device | Feasibility StudyUnited States
-
Klinik Hirslanden, ZurichCompletedNon Inferiority of the Quantra DeviceSwitzerland
-
University of PennsylvaniaPhilips Medical SystemsCompletedThis Study is Being Conducted to Collect Echocardiographic Data to Test the Lumify Ultrasound With Hemodynamic Automation DeviceUnited States
-
Tomey CorporationCompletedEvaluate the Agreement and Precision of Device SS-1000 and the Predicate Device the Pentacam in a Reproducibility and Repeatability TrialJapan
-
Nexstim LtdEnrolling by invitationUsability of the Graphical User Interface of the Device for Its Intended UseFinland
-
PuratosUniversidad de GranadaCompleted
Clinical Trials on FlexStent Femoropopliteal Self-Expanding Stent System
-
Cordis CorporationMassachusetts General Hospital; Prairie Education and Research CooperativeCompletedCardiovascular Diseases | Peripheral Vascular Disease | Peripheral Artery Disease | Vascular Disease | PADUnited States, Belgium
-
Medtronic EndovascularCompleted
-
Acotec Scientific Co., LtdRecruitingPeripheral Arterial Disease (PAD) | Peripheral Vascular Disease (PVD)China
-
Medtronic EndovascularCompletedPeripheral Arterial Disease | Lower Extremity Arterial DiseaseUnited States
-
Sinomed Neurovita Technology Inc.Changhai HospitalActive, not recruitingIntracranial Arterial Diseases | Percutaneous Transluminal Angioplasty | Stent RestenosisChina
-
Medtronic EndovascularCompletedIliofemoral Venous ObstructionUnited States, France, Germany, United Kingdom, Ireland, Italy
-
Terumo Medical CorporationMassachusetts General Hospital; Beth Israel Deaconess Medical Center; ClinLogix...CompletedPeripheral Vascular DiseaseUnited States
-
Abbott Medical DevicesCompleted
-
QualiMed Innovative Medizinprodukte GmbHUnknownPeripheral Artery DiseaseGermany
-
Codman & ShurtleffCompletedIntracranial, Wide-Neck, Saccular Aneurysms